AbbVie (ABBV) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving AbbVie (ABBV) right now is Skyrizi and Rinvoq replacing Humira faster than expected: Skyrizi and Rinvoq generated a combined $25.9 billion in 2025, exceeding AbbVie's own 2027 combined guidance by roughly $500 million two full years ahead of schedule. Revenue (FY 2025, reported) is ~$61.2 billion. If that keeps playing out, the setup is favourable; the risk to it is the single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. No one can predict where ABBV trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive AbbVie (ABBV) higher?
Skyrizi and Rinvoq replacing Humira faster than expected
Skyrizi and Rinvoq generated a combined $25.9 billion in 2025, exceeding AbbVie's own 2027 combined guidance by roughly $500 million two full years ahead of schedule. Forecasts project this duo reaching approximately $50 billion by 2030, powered by label expansions in Crohn's disease, atopic dermatitis, and other inflammatory conditions. The subcutaneous Skyrizi approval in Crohn's, confirmed through the Phase 3 AFFIRM trial, adds a formidable commercial moat in one of the highest-value gastroenterology markets.
Neuroscience becoming a meaningful second growth engine
AbbVie's neuroscience portfolio grew roughly 19.6 percent in 2025 to $10.767 billion, driven by Botox Therapeutic, Vraylar (bipolar depression and schizophrenia), and migraine drugs Ubrelvy and Qulipta. Management has flagged its Parkinson's treatment Vyalev as a potential blockbuster and is targeting a combined migraine franchise of $5 billion or more at peak. This diversification gives AbbVie a revenue base less tied to a single therapeutic class than most peers of similar size.
Prolific free cash flow funds both a growing dividend and M and A optionality
AbbVie generated more than $17.8 billion in free cash flow in 2025, and management guided to approximately $18.5 billion for 2026. That cash engine supports a dividend that has grown for 12 consecutive years at a 12.5 percent compound annual rate since 2013, with a current annualized payout of roughly $6.92 per share. Surplus capital is being directed at pipeline bolt-ons, with more than $5 billion deployed in business development in 2025 alone across platforms in obesity, neuroscience, oncology, and next-generation immunology.
2026 guidance points to durable double-digit earnings growth
Management guided 2026 full-year adjusted EPS to $14.37 to $14.57, representing meaningful acceleration from the $10.00 adjusted EPS reported for 2025, with total net revenue guided to approximately $67 billion, a 9.5 percent increase. The adjusted operating margin is expected to expand, and a PEG ratio near 0.91 (forward basis) suggests the market may be pricing in slower growth than management guidance implies. Analyst consensus forecasts continued EPS growth through 2029 as Skyrizi, Rinvoq, and neuroscience assets compound.
What could weigh on ABBV?
The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, reported at roughly $72.9 billion as of the most recent period, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. Ongoing integration of large acquisitions such as the pending Apogee Therapeutics deal introduces execution risk, and the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles and competition from emerging aesthetic treatments.
How to think about a ABBV forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ABBV guide and whether ABBV is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ABBV outlook
The bottom line: what is driving AbbVie (ABBV) is Skyrizi and Rinvoq replacing Humira faster than expected, with revenue (fy 2025, reported) at ~$61.2 billion. If that keeps playing out the setup is favourable; the risk is the single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. No one can predict the price, so treat any ABBV forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ABBV with Walnut
Use AbbVie as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for AbbVie (ABBV)?
+
No one can reliably predict where ABBV will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push AbbVie higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ABBV higher?
+
The main growth drivers are Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine; Prolific free cash flow funds both a growing dividend and M and A optionality. Whether they play out is the real question, not a guaranteed path.
What are the risks to ABBV?
+
The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, reported at roughly $72.9 billion as of the most recent period, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. Ongoing integration of large acquisitions such as the pending Apogee Therapeutics deal introduces execution risk, and the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles and competition from emerging aesthetic treatments.
Will ABBV stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. AbbVie's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ABBV a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ABBV "is it a buy?" page for a framework. Walnut is not an investment adviser.
What is AbbVie's financial outlook for 2026?
+
Management guided 2026 total net revenues to approximately $67 billion, representing 9.5 percent growth, and adjusted EPS to $14.37 to $14.57, with adjusted operating margin expected to expand to roughly 48.5 percent. Free cash flow is projected at approximately $18.5 billion. The primary growth drivers are continued expansion of Skyrizi and Rinvoq, plus a commercial launch for the Parkinson's therapy Vyalev.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.